July 24, 2017 Licensing, IP, and Legal Life Science Tools M&A, Partnerships PR/Corporate

Agilent Acquires Powerful Next Generation Sequencing IP Portfolio

Molecular and Sample Barcoding IP Portfolio Bolsters Agilent’s Leadership Position in NGS Target Enrichment Solutions IP Portfolio Aimed at Improving Accuracy and Sensitivity of NGS Detection SANTA CLARA, Calif.–(BUSINESS WIRE)–Jul. 24, 2017– Agilent Technologies Inc. (NYSE: A) (“Agilent”) today announced that it has acquired the molecular and sample barcoding patent portfolios of Population Genetics Technologies (“Population... Read more

July 17, 2017 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia

Basel, 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for people with primary progressive multiple sclerosis, a highly disabling form of MS Australia has among the highest prevalence of MS in the Southern... Read more

July 17, 2017 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia

Basel, 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for people with primary progressive multiple sclerosis, a highly disabling form of MS Australia has among the highest prevalence of MS in the Southern... Read more

July 6, 2017 Licensing, IP, and Legal Microscopy

Join the Webinar on Novel Applications of Multiphoton Microscopy on Wednesday, July 12, 2017, 12:00 PM EDT

Adult Thy1-EYFP H line mouse, in vivo (cranial window). Excitatory pyramidal neurons in Layer 5 partly express EYFP. Courtesy of Dr. Masahiro Fukuda and Prof. Haruo Kasai, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan Advances in multiphoton microscopy instruments and technology are leading to unique insights... Read more

June 29, 2017 Licensing, IP, and Legal

ENZO BIOCHEM REPORTS DELAWARE COURT RULING

NEW YORK, NY, June 29, 2017 – Enzo Biochem Inc. (NYSE: ENZ) reported today that a federal judge for the U.S. District Court for the District of Delaware has entered an order in the actions entitled Enzo Life Sciences, Inc. v. Gen-Probe Incorporated, Enzo Life Sciences, Inc. v. Hologic, Inc., Enzo Life Sciences, Inc. v. Roche Molecular... Read more

June 28, 2017 Lab Equipment Lab Top-10 Licensing, IP, and Legal

MilliporeSigma Wins False Advertising Lawsuit Against Distributor of RephiLe Bioscience Lab Water Products

June 27, 2017 MilliporeSigma Wins False Advertising Lawsuit Against Distributor of RephiLe Bioscience Lab Water Products Analis S.A. ordered to cease all illegal advertising following MilliporeSigma lawsuit Belgian distributor claimed RephiLe Bioscience’s lab water purification products were equivalent to MilliporeSigma’s Analis’ advertisements found misleading by Belgian court MilliporeSigma, a leading science and technology company, today... Read more

June 27, 2017 Licensing, IP, and Legal Product Launch

Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)

Basel, 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of Esbriet offers a reduced pill burden for patients with idiopathic pulmonary fibrosis (IPF) People with IPF now have the option of taking one Esbriet... Read more

June 27, 2017 Licensing, IP, and Legal Product Launch

Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)

Basel, 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of Esbriet offers a reduced pill burden for patients with idiopathic pulmonary fibrosis (IPF) People with IPF now have the option of taking one Esbriet... Read more